Physician profile
Kat Deng
NPI 1245979558
$2,937.86
in general payments reported to CMS, 2019-2025
31 companies · $286 in 2025
The $286 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,041 · 2023: $860 · 2024: $750 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,897.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,896.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $500.45 | 2022-2025 | |
| Harmony Biosciences LLC | $295.52 | 2022-2025 | Wakix |
| Ucb, INC. | $265.64 | 2022-2024 | Briviact, Fintepla |
| Novartis Pharmaceuticals Corporation | $246.71 | 2022-2024 | |
| Lilly USA, LLC | $218.68 | 2022-2025 | Amyvid, Emgality, Reyvow |
| Jazz Pharmaceuticals INC. | $173.67 | 2022-2023 | |
| Biogen, INC. | $156.69 | 2022-2025 | Vumerity, Tysabri |
| Argenx US, INC. | $117.15 | 2023-2024 | Vyvgart Hytrulo |
| Sk Life Science, INC. | $105.95 | 2022-2025 | |
| Lundbeck LLC | $85.89 | 2022-2023 | Vyepti, Rexulti |
| Neurelis, INC. | $69.12 | 2022-2024 | Valtoco |
| Pfizer INC. | $60.05 | 2023-2025 | |
| Axsome Therapeutics, INC. | $57.23 | 2024 | Sunosi |
| Avanir Pharmaceuticals, INC. | $56.12 | 2022 | |
| Sumitomo Pharma America, INC. | $55.91 | 2023-2024 | Aptiom |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $49.23 | 2022 | |
| Kyowa Kirin, INC. | $44.38 | 2022-2023 | Nourianz |
| Emd Serono, INC. | $39.34 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $37.08 | 2022 | |
| Amneal Pharmaceuticals LLC | $35.60 | 2022-2023 | Rytary |
| Livanova USA, INC. | $32.53 | 2022-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Teva Pharmaceuticals USA, INC. | $32.08 | 2022-2024 | Austedo Xr |
| Neurocrine Biosciences, INC. | $31.12 | 2022 | |
| Eisai INC. | $28.81 | 2024 | |
| Boston Scientific Corporation | $26.99 | 2024 | General - Therapies |
| Averitas Pharma INC. | $25.77 | 2024 | Qutenza |
| Genentech USA, INC. | $24.02 | 2022 | |
| Aucta Pharmaceuticals, INC. | $20.76 | 2024 | Motpoly Xr |
| Sunovion Pharmaceuticals INC. | $17.81 | 2022 | |
| Vanda Pharmaceuticals INC. | $16.32 | 2024 | Ponvory |
| Corium, LLC | $11.24 | 2023 | Adlarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kat Deng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.